Lab21 in Cambridge UK and Baltimore-based BD Diagnostics are collaborating to develop oncology assays for the BD MAX™ fully automated, bench-top molecular system.

US medical device business HemoSonics has chosen leading technology hothouse Cambridge Consultants in the UK to finalise development of a new diagnostic instrument deigned to counter excessive bleeding or blood clotting in surgery.

Drug discovery technology business, Optibrium, has expanded its team and moved to larger headquarters in Cambridge UK after growing its global customer base.

KidzEyez, a novel visual field analyser for young children, won the medical technology prize in Health Enterprise East’s Innovation Awards 2012 in Cambridge UK.

New and advanced diagnostic technology that offers early detection of prostate and lung cancer is being taken into the workplace by Cambridge-based HealthScreen UK.

Three Cambridge UK biomed technology powerhouses today reaffirmed their commitment to the open innovation agenda through a new initiative at the heart of the Cambridge cluster.

TAP Biosystems in Cambridge and University College London in the UK are collaborating to develop a new technology weapon designed to fight cancer.

Only an interdisciplinary approach by the scientific research community will solve the growing problem of disease in an ageing population, a Cambridge UK technology summit was warned.

Personalised medicines pioneer Horizon Discovery has developed a new weapon in the fight against ‘undruggable’ cancer genes.

Cambridge UK healthcare technology specialist How are you? has launched a new app store with The European Directory of Health Apps 2012-2013 – claiming the first-ever directory and app store of its kind.

Cancer drug discovery business, Sareum, saw its losses deepen in the year to June 30 but the Cambridge UK company believes its first big deal is just around the corner.

A Cambridge UK pharmaceutical company has reported positive results from a new study into preventing acute nausea and vomiting in cancer patients.

Endomagnetics, the Cambridge UK company developing technology to improve the standard of breast cancer management, has achieved certification to an international quality standard.

Cambridge drug delivery business Vectura is set to collect a $10 million windfall from Novartis and earn subsequent royalty streams following a key approval for pioneering inhaler technology.

AstraZeneca has agreed a collaboration with Roche Diagnostics to develop companion diagnostics for selected products in development at AZ and MedImmune, which has a major and growing operation in the Cambridge UK technology cluster.

The Japanese government has handed a key approval to capsules for an inhaler device based on technology from Cambridge-based Vectura – handing the UK company a £2.5m milestone payment from partner Novartis.